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Introduction: 13C‐breath tests are valuable, noninvasive diagnostic tests that can be
widely applied for the assessment of gastroenterological symptoms and diseases.
Currently, the potential of these tests is compromised by a lack of standardization
regarding performance and interpretation among expert centers.
Methods: This consensus‐based clinical practice guideline defines the clinical in-
dications, performance, and interpretation of 13C‐breath tests in adult and pediatric
patients. A balance between scientific evidence and clinical experience was achieved
by a Delphi consensus that involved 43 experts from 18 European countries.
Consensus on individual statements and recommendations was established if ≥ 80%
of reviewers agreed and <10% disagreed.
Results: The guideline gives an overview over general methodology of 13C‐breath
testing and provides recommendations for the use of 13C‐breath tests to diagnose
Helicobacter pylori infection, measure gastric emptying time, and monitor pancreatic
exocrine and liver function in adult andpediatric patients.Other potential applications
of 13C‐breath testing are summarized briefly. The recommendations specifically detail
when andhow individual 13C‐breath tests should be performed including examples for
well‐established test protocols, patient preparation, and reporting of test results.
Conclusion: This clinical practice guideline should improve pan‐European harmo-
nization of diagnostic approaches to symptoms and disorders, which are very
common in specialist and primary care gastroenterology practice, both in adult and
pediatric patients. In addition, this guideline identifies areas of future clinical
research involving the use of 13C‐breath tests.
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INTRODUCTION
Breath tests are valuable, noninvasive diagnostic tests that are
widely applied for the assessment of gastroenterological symptoms
and diseases. 13C‐breath tests provide the opportunity to diagnose
Helicobacter pylori (H. pylori) infection, document gastric emptying
time, monitor pancreatic exocrine and liver function, and have
several additional potential gastroenterological and non-
gastroenterological applications.
Currently, the potential of breath testing is compromised by a
lack of standardization regarding performance and interpretation
among expert centers. This is highly relevant because modifications
of the volume and/or composition of the test meal, of test perfor-
mance and of the evaluation of data may markedly influence test
results, diagnosis and thus, clinical usefulness of the investigation.
This consensus‐based clinical practice guideline is needed within
the gastrointestinal (GI) community to enhance pan‐European
harmonization of diagnostic approaches to symptoms and disor-
ders, which are very common in specialist and primary care
gastroenterology practice, both in adult and in pediatric patients. The
guideline can add significantly to quality of investigation and, thus,
the welfare of gastroenterological patients because it will allow a
more rational approach to diagnostic evaluation and treatment. The
guideline also aims to minimize disparities between health care sys-
tems across Europe, to facilitate cooperation between expert groups
and the performance of multicenter clinical trials.
METHODS
The structured procedure, which was developed for the creation of
this consensus‐based clinical practice guideline, has previously been
published.1 Briefly, this procedure was initiated by three represen-
tatives of the contributing societies (heads of guideline, JK, HH, MF)
and started with formation of a representative core group of experts
nominated from all participating societies and associations. This core
group developed statements and recommendations, which were then
submitted to reviewers in a three‐stage Delphi voting process. The
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heads of guideline and the core group members are listed as authors;
the reviewers are listed as members of the European 13C‐breath test
group.
The following key questions were addressed in the guideline:
1. What is the role of 13C breath tests in the detection of H. pylori
infection, and in the measurement of gastric emptying, pancreatic
exocrine and liver function?
2. What are the general technical requirements and operating pro-
cedures for performance of 13C‐breath tests, including prepara-
tion, dosage, breath sampling, technical analysis?
3. What are the reporting requirements?
4. Are there areas of disagreement and research priorities?
A systematic literature search with the appropriate key words
using Medline/Pubmed and the Cochrane database was performed.
We limited our search to studies performed in humans, which were
published between 01 January 2000 and 25 July 2019. The
resulting 446 references were assessed and allocated to the
following topics: general methodology, 13C‐urea breath tests (13C‐
UBT), 13C‐gastric emptying breath tests (13C‐GEBT), 13C‐pancreatic
function breath tests (13C‐PFBT), 13C‐liver function breath tests
(13C‐LFBT), and other 13C‐breath tests. Statements and recom-
mendations were developed based on these results, relevant
consensus documents including those of participating societies
(published after the year 2000),2 and on pertinent literature known
to members of the core group. Statements reflect key aspects and
definitions but give no direct instructions on how to act, whereas
recommendations advise when and how to perform individual 13C‐
breath tests and how to report on breath test results. The wording
used to indicate the strength of recommendation is detailed in
Table 1.1
Of note, we aimed to develop recommendations on the specific
indications for 13C‐breath tests, whereas general indications for H.
pylori testing, gastric emptying testing and monitoring of pancreatic
exocrine or liver function were cited from current national and inter-
national guidelines.
Statements and recommendations were distributed among all
reviewers via email for voting and commenting. All reviewers voted
on all statements and recommendations according to the 6‐point
Likert scale given in Table 21 and gave comments in case of
disagreement. “Agreement” was established if ≥ 80% of reviewers
voted A+/A AND < 10% D+/D.
Statements and recommendations, which did not receive agree-
ment during the first Delphi round, were modified according to
comments as previously described,1 and all modified statements and
recommendations underwent further rounds of the Delphi process.
Statements that achieved “agreement” after three Delphi rounds
were accepted. Percentages for agreement and disagreement are
given for all recommendations and statements. Recommendations
additionally include quality of evidence (Q) and strength of recom-
mendation (S).1
The guideline is organized in a way that information, which will
enable the reader to perform clinical tests, is summarized in state-
ments, recommendations and respective tables. Background infor-
mation detailed in the comments explains the choice of test protocols
and further methodological aspects.
GENERAL 13C‐BREATH TEST METHODOLOGY
Since their introduction into clinical practice in the 1970s,3 stable
isotope 13C‐breath tests have gained considerable importance and
TAB L E 1 Descriptors of grading1
Descriptor Meaning Wording
A—Strength high Evidence or general accord that the procedure or statement is useful or effective. Further




B—Strength moderate Conflicting evidence or discordant opinions that the procedure or statement is useful or
effective. The weight of evidence/opinion is in favor of utility. Further research is likely




C—Strength low Conflicting evidence or discordant opinions that the procedure or statement is useful or
effective. Further research is very likely to have an important impact on our confidence
in the estimate of effect and is likely to change the estimate
…could…
D—Strength very low Any estimate of effect is very uncertain …may…
TAB L E 2 Six‐point Likert‐scale1
Point Description
A+ Agree strongly
A Agree with minor reservation
A− Agree with major reservation
D‐ Disagree with major reservation
D Disagree with minor reservation
D+ Disagree strongly
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have been recommended for distinct diagnostic purposes by national
and international guidelines and expert consensus papers.4–7 This is
due to the fact that they are not only reliable, but also noninvasive,
relatively simple and safe diagnostic tools. 13C is a stable, nonra-
dioactive carbon isotope with a natural abundance of about 1% of
carbon isotopes. The use of non‐radioactive stable‐isotope tracers in
biomedical experiments and diagnosis is generally considered ethi-
cally acceptable in humans at all ages. Toxicity of 13C has been
examined in animals given amounts far in excess of those employed
in the clinic. Up to sixty percent enrichment with 13C was achieved
over prolonged periods of time without negative effects in adult
animals and without signs of teratogenicity or embryotoxicity.8–10
Thus, the small requirements of 13C as a tracer in most clinical
studies, particularly relative to its naturally high abundance, pre-
cludes any discernible risk of toxicity. Accordingly, 13C‐enrichment of
marker substances does not affect their tolerability. Depending on
pharmacological properties of the marker substance itself, most
clinically established 13C‐breath tests can also be performed
(repeatedly) in young children and pregnant women. This chapter
gives important background information on methodological aspects
and delineates general recommendations on test performance.
Statement 1.1 13C‐breath tests are used for investigation of a
variety of gastrointestinal and liver functions and for diagnosis of
Helicobacter pylori infection (100%, 0%).
In addition to the clinically established indications extensively
discussed in this consensus report, several other tests have been
developed for gastroenterological and other purposes (compare
“Other tests”).
Statement 1.2 The general principle requires that the digestive/
metabolic process under investigation represents the rate‐
limiting step in the sequence of events leading to occurrence of
13CO2 in the exhaled air (100%, 0%).
For instance, within the time frame used for testing, the presence
of bacterial urease in the stomach determines whether 13C‐urea is
metabolized leading to a selective increase in 13CO2‐exhalation in H.
pylori positive patients.
Statement 1.3 Most 13C‐breath tests require sample collection
and measurement over several hours. For selected indications (e.
g., 13C‐urea breath test in adults) measurements at two time
points can be sufficient (100%, 0%).
Analysis of 13C‐breath tests is frequently based on kinetic data of
the 13CO2 exhalation characteristics (e.g., gastric emptying tests) or
on quantitative analysis of the whole metabolic process, that is, by
analysis of cumulative 13CO2 exhalation (e.g., pancreatic or liver
function tests). Accordingly, several breath samples have to be
collected at predefined intervals. Depending on the metabolic and
whole body distribution pathways of each 13C‐labeled substrate and
the process under investigation, breath sampling over several hours
may be necessary. For instance, protocols for pancreatic function
testing usually require 4 to 9 h of sample collection at 15 or 30 min
intervals.11–14 On the other hand, 13C‐UBT in adults are usually
based on two point measurements.15,16 However, even for H. pylori
testing, some experts calculate cumulative 13C‐exhalation over 1 h
based on breath samples collected at 15 min intervals. The major
advantage is that the patient's anthropometry is taken into account: a
small and light person has a much higher measurement of δ over
baseline value (DOB) than a very tall and heavy person for the same
cumulative percentage of administered dose. In this way, the test can
also be applied in children.
Statement 1.4 Isotope‐ratio mass spectrometry is the reference
method for measurement of the 13CO2 concentration in the
exhaled air (100%, 0%).
Statement 1.5 Isotope‐selective nondispersive infrared spec-
troscopy can be used alternatively (91%, 0%).
At present, mass‐spectrometry is the most accurate and efficient
method for measuring carbon isotope ratios in exhaled breath
(IRMS), but its application is restricted by the high cost of the
equipment and operational complexity. Nondispersive infrared
spectrometry (NDIRS) is the most widely used alternative method.
Apart from lower costs, the devices are smaller, easier to handle and
can be used on site, for example, in outpatient facilities.17 On the
other hand, NDIRS measurements usually require higher sample
volumes. Samples are frequently collected in aluminum bags (200–
1300 ml) instead of 10 ml glass tubes as used for IRMS, which limits
its use in large laboratories to which samples are delivered from
distant sites.
Studies comparing the results of IRMS and NDIRS measurements
of identical samples have shown comparable results for both
methods. Most of these studies have investigated samples from 13C‐
UBT.17–21 Data show correlation coefficients of up to 0.999 for both
analytical methods. A meta‐analysis assessing the diagnostic accu-
racy of 13C‐UBT in adult patients with dyspepsia showed no signifi-
cant difference for studies reporting NDIRS or IRMS results.22
Similarly, results of 13C‐octanoic acid breath tests (13C‐OABT),
which measure gastric emptying, have been compared using IRMS
and NDIRS.23 As expected, precision and repeatability of 13C‐
measurements with NDIRS were inferior to IRMS. However, corre-
lation coefficients for 13C‐exhalation and all gastric emptying pa-
rameters as computed on the basis of IRMS and NDIRS
measurements were >0.98. Mean gastric emptying half time calcu-
lated using nonlinear regression (NLR) analysis was almost identical
(87 ± 39 min vs. 90 ± 39 min). For the 13C‐methacetin breath test, a
dynamic liver function test, molecular correlations spectroscopy, a
method similar to NDIRS, showed comparable results to IRMS in
Bland‐Altman and correlation analysis.24 Breath samples were
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collected continuously via a nasal cannula with one sample analyzed
about every 3 min.
Theoretically, these results should be transferable to other 13C‐
breath tests since 13CO2 is the ultimate metabolic product, which is
analyzed in all of these tests. However, caution may be necessary
when applying tests, that only result in small increases in 13C‐
exhalation, for example, 13C‐pancreatic function tests, for which
highly accurate measuring devices are required.25
Statement 1.6The δ‐value (‰) is themeasuring parameter and is
defined as the 13CO2/
12CO2 ratio in a given sample in comparison
to the 13CO2/
12CO2 ratio in a reference material (97%, 0%).
Statement 1.7 Differences between δ‐values obtained after
application of a marker substance and the baseline δ‐value (δ
over baseline, DOB) are used for calculation of outcome pa-
rameters (97%, 0%).
Conventionally, 13C‐content of breath samples is expressed as δ
‰ PDB units, that is, relative to the international standard, which
originally was the calcium carbonate of the fossil Belemnitella of the
Pee Dee formation (PDB) in South Carolina, USA. Zero δ ‰ corre-
sponds to 1.112372% 13C atoms within CaCO3. Thus, if a sample of
carbon dioxide has a 13C/12C ratio which is less than that of the
standard by 5 per mil, it is said to have a δ‐value of −5‰.26,27 DOB
values are the differences between δ‐values obtained before (base-
line) and after application of the marker substance. They reflect the
increase in 13C‐exhalation, which is the basis for calculation of test
parameters. For most established 13C‐UBT‐protocols, the DOB value
at 30 min is the relevant outcome parameter (compare below). For
most other tests, based on DOB values and the assumption of a
stable CO2‐production rate of 300 mmol per square meter of body
surface per hour, the quantity of 13C appearing in breath per unit
time is calculated. These data are usually expressed as percentage of
13C‐dose administered.
Statement 1.8 13CO2 concentrations in samples collected using
breath tubes for isotope‐ratio mass spectrometry (IRMS) remain
stable for at least 4 weeks so that measurement of breath
samples can be delayed by this period (84%, 0%).
Statement 1.9 13CO2 concentrations in samples collected using
aluminum bags for nondispersive infrared spectroscopy (NDIRS)
remain stable for at least 72 h so that measurement of breath
samples can be delayed by this period (93%, 0%).
For IRMS, stability of samples for a minimum period of 4 weeks
has been demonstrated. A brief report even suggests that with
10 ml samples stored in glass tubes at room temperature in the
absence of light, 13C‐concentrations are stable for 8 months.28 For
NDIRS there are hardly any published data on sample stability.
Mana et al. showed that samples are stable for 72 h.18 Personal
experience of the authors suggests longer stability (1‐2 weeks by
additional sealing of the rubber tubes of aluminum bags with gas‐
tight tapes).
Statement 1.10 Digestive and metabolic processes can be
influenced by several factors including demographic parameters,
fasting or fed state, composition and size of a test meal, physical
activity, pre‐existing diseases and drug intake (100%, 0%).
13C‐exhalation from marker substances depends not only on the
process under investigation (e.g., gastric emptying), but also on ab-
sorption of the marker substance and/or its metabolites, further
(mostly hepatic) metabolism leading to production of 13CO2, its
transport to the lung and pulmonary excretion and distribution to
other body compartments leading to a relevant loss of label, for
example, into muscles or bone.29 All of these functions as well as the
process under investigation can be influenced by demographic and
physiological parameters, concomitant diseases and drug intake.30–40
A study investigating the influence of clinical parameters on the re-
sults of 13C‐OABT in more than 1200 patients has shown that 13C‐
exhalation was increased in women and correlated with age. Dia-
betes mellitus and inflammatory bowel disease were associated with
decreased, and bacterial overgrowth and malignant disease with
increased 13C‐exhalation.39
Figure 1 summarizes the general principle of 13C‐breath testing.
What are the general prerequisites for performance
of 13C‐breath tests for clinical or research purposes?
Recommendation 1.1 13C‐breath tests performed for clinical reasons
have to adhere strictly to standardized study protocols adequately
validated in a representative patient population (100%, 0%; Q:C S:
A).
Recommendation 1.2 For research projects, test parameters such as
composition of the test meal or duration of breath sampling can be
varied to evaluate the impact of the variation on test results (89%,
3%; Q:D S:B).
As discussed above, 13C‐breath tests are indirect tests depending
on several digestive and metabolic processes, which ultimately lead
to exhalation of 13C‐enriched breath. All intermediary steps as well
as the process under investigation can be influenced by demographic
and physiological parameters, concomitant diseases and drug intake.
Moreover, alterations of marker substance, dose, or other compo-
nents of the test meal/solution can markedly influence test results.
Accordingly, it is of pivotal importance that tests are validated in
representative patient populations and that clinicians adhere to
strictly standardized study protocols. Research projects are required
to better delineate the impact of variations on test results in order to
optimize test procedures.
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Which dietary restrictions need to be observed before
13C‐breath testing?
Recommendation 1.3 13C‐rich food, ingested before the test (e.g., corn,
pineapple, broccoli, sugarcane) can increase the baseline δ‐value
and thereby compromise the measurements. Accordingly, they
should be avoided at least 48 h before 13C‐breath testing (85%,
0%; Q:C S:B).
Isotopic fractionation—change in isotopic ratios between mate-
rials, due to the different rates at which various isotopes undergo
chemical reactions—is a well‐established phenomenon.27 Carbon
isotopes are strongly fractionated during photosynthesis, when
plants metabolize carbon dioxide. Three types of photosynthesis
occur in the plant world, commonly referred to as the C3, C4, and
CAM pathways.27 While most plants traditionally consumed in Eu-
ropean diets perform C3 photosynthesis, leading to comparably
lower 13C‐content, other plants such as corn, pineapple, broccoli, and
sugarcane are C4 plants with relatively higher 13C‐abundance. Their
consumption prior to a 13C‐breath test increases basal 13C‐
exhalation, and further metabolization may influence 13C‐
exhalation over time. Avoidance for 48 h before breath testing is
deemed satisfactory by most experts, while some recommend 72 h.
Which drugs and medical interventions need to be
avoided before and during 13C‐breath testing?
Recommendation 1.4 Drugs with potential influence on test results
should be avoided before the test, unless essential long‐term
medication is concerned or the effect of the drug on the
digestive/metabolic process is to be determined (92% 0%; Q:D
S:B).
Recommendation 1.5 Dialysis solutions and glucose infusions mostly
contain glucose that originates from hydrolysis of maize starch
naturally enriched in 13C and should therefore be avoided during
13C‐breath testing (94%, 0%; Q:D S:B).
Drugs can influence test results by altering GI transit, absorption
or (postabsorptive) metabolism of the 13C‐labeled substrate.
Accordingly, reliable performance of 13C‐breath tests may require
avoidance of specific drugs as discussed for the individual tests
below. However, if long‐term treatment is mandatory, drug avoid-
ance is not always reasonable because it confounds the normal
clinical situation of the patient. Moreover, 13C‐breath tests can be
used for monitoring drug effects. For instance, the 13C‐mixed tri-
glyceride breath test (13C‐MTGBT) has been used to monitor
improvement of lipid absorption with enzyme replacement therapy in
pancreatic exocrine insufficiency (PEI).11
Dialysis solutions and glucose infusions mostly contain glucose
that originates from hydrolysis of maize starch, so that they are
naturally enriched in 13C. Accordingly, they may confound test re-
sults and should also be avoided.37
Is physical activity allowed during 13C‐breath testing?
Recommendation 1.6 Physical activity alters gastrointestinal transit of
orally administered substrates and markedly increases CO2
F I GUR E 1 General principle of 13C‐breath testing. The 13C‐marked substrate is ingested, frequently with a specific test meal or test
solution. Hepatic or bacterial enzymes release 13CO2, this requires prior intraluminal metabolization and/or intestinal absorption for most
tests. 13CO2 is absorbed into the blood stream, transported to the lung, and exhaled. Breath samples are collected in glass tubes (mass
spectroscopy) or aluminum bags (infrared spectroscopy) for measurement of 13C/12C‐ratio. Delta over basal values are used for calculation of
13C‐excretion. * for specific liver function tests the 13C‐marked substrate is applied intravenously
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production. Therefore, physical activity has to be avoided during
13C‐breath testing (100%, 0%; Q:C S:A).
Even moderate physical activity such as walking roughly doubles
energy expenditure compared with sedentary subjects and has corre-
sponding effects on endogenous CO2 production.
41,42 In addition, ex-
ercise leads to a shift toward oxidation of nonlipid components. This
increases 13C‐exhalation because the lipid molecules in the body
contain substantially lower concentrations of 13C than the nonlipid
molecules, due to fractionation processes during lipid synthesis.35
Moreover, 13C‐breath tests using orally applied marker substances
depend on GI transit which is accelerated by moderate exercise, while
strenuous exercise has opposite effects.43 Accordingly, it has been
shown that physical activity during 13C‐OABTmarkedly alters 13CO2‐
exhalation in healthy volunteers as well as respective normal values.36
In summary, physical activity has profound and complex effects
on 13C‐exhalation and breath test results. For standardization pur-
poses under clinical conditions, patients must be asked to strictly
avoid physical activity during tests.
Which concomitant diseases may influence 13C‐
breath test results?
Recommendation 1.7 Disturbances of gastrointestinal motor and
secretory function, hepatic and pulmonary function can generally
affect the time course and/or amount of 13C‐exhalation. This has
to be taken into account for performance and interpretation of
13C‐breath tests (100%, 0%; Q:B S:A).
Concomitant diseases affecting digestive and metabolic
processes which ultimately lead to exhalation of 13C‐enriched
breath may confound breath test results. In particular, major
disturbances of GI transit and absorption, hepatic and lung
function have to be considered. However, the influence of
concomitant diseases on many 13C‐breath tests appears to be
small:
Even in patients with nonalcoholic steatohepatitis or liver
cirrhosis (∼50% Child–Pugh score C), 13C‐octanoic acid metabolism
was found to be normal44–46 and the 13C‐OABT correlated well with
scintigraphy in patients who were critically ill.47
Disturbances of 13CO2‐exhalation in patients with lung dis-
eases are only expected in patients with very severe disease
and reduced CO2‐diffusion capacity. Data on potential impair-
ment of 13C‐breath tests in such cases are not available in the
literature.
Since digestion of dietary lipids by pancreatic lipase cannot occur
before the meal has entered the duodenum, results of the 13C‐MTGT
are influenced by and correlate with gastric emptying parameters.14
This predominantly applies to early postprandial 13C‐exhalation rates
(1–3 h), which have insufficient specificity for detection of PEI.
However, this problem can be overcome by prolongation of the
breath sampling period so that gastric emptying is of minor impor-
tance for 13C‐exhalation.
Vice versa, 13CO2‐excretion following administration of 13C‐
octanoic acid was similar in patients with and without PEI,
including those with severe exocrine insufficiency characterized by
overt steatorrhea.39,48,49
13C‐UREA BREATH TEST
H. pylori is a common bacterial pathogen responsible for substantial
GI morbidity worldwide. In addition to causing inflammatory
gastroduodenal alterations, H. pylori is the major risk factor for
gastric cancer development and is associated with various other,
partly non‐GI diseases. Table 3 summarizes important indications for
H. pylori testing in adults and children recommended by current Eu-
ropean guidelines.4,5
There are differences in the approach to H. pylori infection be-
tween adults and children. Thus, the European Society of Pediatric
Gastroenterology, Hepatology, and Nutrition (ESPGHAN) explicitly
recommends against a test and treat strategy in children, as well as
against H. pylori testing as part of the initial investigation in children
TAB L E 3 Indications for H. pylori testing in adults and children4,5
Grade of recommendation
Adults High Suspicion/evidence of peptic ulcer disease, atrophic gastritis, gastric adenocarcinoma,
MALT (mucosa‐associated lymphoid tissue) lymphoma
Test‐and‐treat strategy for uninvestigated dyspepsia
Exclusion of H. pylori gastritis before reliable diagnosis of functional dyspepsia
Moderate Aspirin and NSAIDs users with a history of peptic ulcer
Low Unexplained iron deficiency anemia, idiopathic thrombocytopenic purpura, vitamin B12
deficiency
Children High Suspicion/evidence of peptic ulcer disease
Monitoring of outcome of eradication therapy
Low Chronic immune thrombocytopenic purpura
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with iron deficiency or as part of the investigations of causes of short
stature. Moreover, these guidelines recommend against H. pylori
testing in children with functional abdominal pain disorders.5
For the diagnosis of H. pylori infection, histology (±culture) from
biopsy samples is regarded as the reference standard.50,51 Several
other tests are available, including endoscopic biopsy followed by
rapid urease testing and noninvasive methods like serology, fecal
antigen tests and the 13C‐UBT. The principle of the 13C‐UBT relies
upon the capacity of H. pylori, when present in the stomach, to hy-
drolyze orally administered 13C‐urea to produce 13CO2, which dif-
fuses into the blood, is transported to the lungs and exhaled, so that
it can be detected in breath samples. 13C‐urea is innocuous and can
be safely administered repeatedly, including in children and pregnant
women.
According to the Maastricht V/Florence Consensus report, 13C‐
UBT is regarded as the best approach to the diagnosis of H. pylori
infection in the context of a “test‐and‐treat strategy” in adults
because of its high sensitivity and specificity, and excellent perfor-
mance.4 This is confirmed by a recent Cochrane review showing su-
perior diagnostic accuracy compared with other non‐invasive tests.50
Stool antigen tests may be less acceptable in some societies but
also have a high sensitivity and specificity, provided a monoclonal
antibody‐based ELISA is used.4 Some serology tests have high
sensitivity and specificity, but these tests may perform differently in
different geographic locations according to the antigenic composition
of the circulating strains. Thus, the Maastricht V/Florence Consensus
recommends that only locally validated tests should be used.4
Moreover, due to the slow decrease of serum antibody levels, they
are inadequate for assessment of H. pylori eradication after
treatment.
In clinical practice when there is an indication for endoscopy, and
there is no contraindication for biopsy, the rapid urease test (RUT) is
recommended as a first‐line diagnostic test. In the case of a positive
test, it allows immediate treatment.4
When should 13C‐UBT be utilized?
Recommendation 2.1 The 13C‐urea breath test is to be considered as a
noninvasive alternative for all indications for Helicobacter pylori
testing if endoscopy is not required or if biopsies are contra-
indicated (92%, 0%; Q:A S:A).
Recommendation 2.2 The 13C‐urea breath test is a preferred option for
confirmation of Helicobacter pylori eradication in adults and
children. It has to be performed at least 4 weeks after completion
of therapy (89%, 0%; Q:A S:A).
Meta‐analyses confirm that 13C‐UBT achieves ≥95% sensitivity
and specificity in both adults and children.50,52 Accordingly, it is a
highly accurate test and generally appropriate for all indications for
H. pylori testing. However, in clinical practice, when there is an
indication for endoscopy, and there is no contraindication for biopsy,
the RUT is recommended as a first‐line diagnostic test.4 Some na-
tional guidelines suggest two positive tests for reliable diagnosis,
except in cases with a very high a priori likelihood of H. pylori
infection, for example, duodenal ulcer,53 and 13C‐UBT can be readily
performed. Moreover, 13C‐UBT is regarded as the best option for
confirmation of H. pylori eradication,4,50 with stool antigen tests being
an alternative. Testing has to be delayed for at least 4 weeks after
the end of therapy, otherwise it may lead to false negative results
(compare patient preparation).
How should 13C‐UBT be performed?
Recommendation 2.3 If commercially available kits are used for 13C‐
urea breath test, manufacturers' instructions regarding prepara-
tion of test solution and test performance have to be followed
(97%, 0%; Q:B S:A).
Recommendation 2.4 If the test is prepared on site, investigators have to
adhere to well established test protocols (for examples compare
Table 4) (97, 0%, 0%; Q:B S:A).
As discussed above, alterations of marker substance, dose or
other components of the test meal/solution can markedly influence
test results. Hence, it is of pivotal importance that tests are vali-
dated in representative patient populations and that clinicians
adhere to strictly standardized study protocols. Since the original
description of the 13C‐UBT by Graham et al.,57 several changes of
the test protocol have been proposed affecting the dose of 13C‐
urea, type of test meal/solution, time of breath collection, cut‐off
values, and measuring device.58 Logan et al. first introduced a
modified version with only one breath sample to be analyzed,
however this was pooled from several samples collected over
30 min at 5 min intervals.59 Currently, most studies report DOB
values of a single sample collected 30 min after application of 13C‐
urea with a threshold of >4‰ for diagnosis of H. pylori infection. At
this threshold the summary sensitivity (95% confidence interval
[CI]) and specificity (95% CI) from 10 studies (958 participants)
were 0.95 (95% CI: 0.79–0.99) and 0.95 (95% CI: 0.87–0.98).50 A
minority of studies used sampling periods of 10 or 20 min and
thresholds between DOB>3‰ and DOB>6‰.50 13C‐urea was
usually applied with a citric acid solution; however, orange juice54
or semiliquid meals have also been used.55 Examples for well‐
established test protocols are given in Table 4.
How should patients prepare for the test?
Recommendation 2.5 Ideally, adult patients should have fasted over-
night. If this is not feasible, a fasting period of 4 to 6 h is sufficient
(97%, 0%; Q:C S:B).
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Recommendation 2.6 Children of all ages should have fasted for 4 h
(100%, 0%; Q:B S:B).
Theoretically, food in the stomach may dilute the marker sub-
stance and thereby impair the contact between the infected mucosa
and the substrate leading to lower 13CO2 production and decreased
sensitivity of the test. Although this aspect is still controversial, some
studies suggest that fasting before the 13C‐UBT indeed improves
accuracy of test results.18,60 Accordingly, it appears to be prudent to
perform the 13C‐UBT in fasting conditions.60 In adults, fasting over-
night appears reasonable. If this is not feasible, a fasting period of 4–
6 h is deemed sufficient. In young children, long fasting periods may
be problematic. However, sensitivity of the 13C‐UBT was markedly
reduced to about 50% when children were fed a meal immediately
before the test.61 Therefore, a fasting period of 4 h is suggested,
including in young children.
Recommendation 2.7 Prior to the 13C‐urea breath test patients have to
abstain from: proton pump inhibitor therapy for ≥2 weeks; anti-
biotic therapy (including Helicobacter pylori eradication)
for ≥ 4 weeks (97%, 0%; Q:A/B S:A).
Recommendation 2.8 Antacids can be allowed before the 13C‐urea
breath (86%, 0%; Q:B S:B).
Proton pump inhibitors (PPI) need to be discontinued because
they decrease the load of H. pylori leading to false‐negative results on
several tests including 13C‐UBT.4,62,63 A 7‐day withdrawal has been
shown to be sufficient in most patients; however, as a precaution,
14 days are recommended.4 H2‐receptor antagonists slightly
decrease sensitivity of 13C‐UBT for up to 2 weeks.64 Topical antacids
do not affect sensitivity62 so that they can be allowed before testing.
By contrast, antibiotics, including those used for eradication therapy,
and bismuth compounds need to be discontinued for 4 weeks to
allow an increase of a detectable bacterial load.4
How should test results be reported?
Recommendation 2.9 To allow for reliable interpretation of test results,
the following parameters should be reported: marker dose and test
solution; test result including normal values and interpretation
(Helicobacter pylori negative/positive) (95%, 0%; Q:D S:B).
Recommendation 2.10 The test report could be complemented by
including clinical characteristics of the patient, last use of proton
pump inhibitor and the exact test protocol including equipment
used for breath sampling and analysis (84%, 0%; Q:D S:C).
Experts agree that a minimum of information on methodology
(marker dose and test solution) and test results (e.g., DOB‐value)
including normal values and interpretation (H. pylori positive/nega-
tive) are required for medical personnel not involved in the testing to
reliably interpret individual findings. Clinical characteristics of the
patient including last use of PPI and further methodological infor-
mation may further facilitate assessment of reliability of test results
and choice of clinical consequences.
13C‐GASTRIC EMPTYING BREATH TESTS
Gastric dysmotility can manifest as rapid gastric emptying with
dumping syndrome (even in the absence of upper GI surgery) or
delayed gastric emptying with symptoms of gastroparesis. The latter
applies to the majority of affected patients and is typically associated
with nausea, vomiting, early satiety, postprandial fullness, upper
abdominal pain, and bloating in adults and children.6,65–69 Anorexia
and weight loss are further frequent symptoms. Children with gas-
troparesis experience more vomiting while adolescents with gastro-
paresis report more nausea and abdominal pain.68,70 There is general
consensus that the diagnosis of gastroparesis requires objective ev-
idence of clearly delayed gastric emptying in symptomatic
TAB L E 4 Established test protocol for 13C‐UBT in adults and children
Reference Test solution Breath sampling Cut off Validity Remarks
Leodolter 199915 Adults 75 mg 13C‐urea dissolved
in 200 ml 0.1 mol/L
citric acid solution
(∼4 g/200 ml
water) with two tablets
artificial sweetener





Equal performance as test with citric
acid solution 10 min before marker
ingestion;
With 200 ml orange juice instead of
citric acid lower SENS (88%) with
equally high SPEC (100%)54; with
semiliquid meals longer test
duration required55
Elitsur et al. 200956 Children 75 mg 13C‐urea and
2 g citric acid dissolved
in 4 ounces (∼120 ml)
potable water
Baseline and 15 min
after ingestion
≥2.4‰ SENS 97.9% Test performed best in children aged
>6 years; in ages 2–5 calculation
of urea hydrolysis rate can lead to





Abbreviations: ACC, accuracy; DOB, δ over baseline; NPV, negative predictive value; PPV, positive predictive value; SENS, sensitivity; SPEC, specificity;
UBT, urea breath test.
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patients.6,66 However, prior to gastric emptying testing, the exclusion
of mucosal or structural disorders such as inflammatory or malignant
diseases as the underlying cause of symptoms is required.6 Specific
indications for gastric emptying testing in adults as suggested by
international guidelines and expert consensus papers are given in
Table 5.6,65,71 For pediatric patients, there are no generally accepted
guideline recommendations on gastric emptying testing. The recom-
mendations given in Table 5 are derived from a recent review of the
literature, which shows that nausea, vomiting, and abdominal pain
are the most common symptoms in children, while early satiety,
postprandial fullness, bloating, and weight loss occur less frequently
in pediatric gastroparesis.72
When should 13C‐GEBT be utilized?
Recommendation 3.1 13C‐gastric emptying breath tests are to be
regarded as an established alternative to scintigraphy for mea-
surement of gastric emptying velocity (92%, 0%; Q:A S:A).
Scintigraphy is the reference standard for measurement of
gastric emptying. However, while there is a consensus report rec-
ommending a standardized protocol in adults in the United States,73
no European consensus exists on the type of test meal and duration
of data acquisition. Likewise, no consensus exists for a standard
gastric emptying scintigraphy in pediatrics. However, recent studies
have provided confirmation that extending studies from 2 to 4 h
increases the diagnostic yield and should be the standard in children
and adolescents as it is in adults for measurement of solid gastric
emptying.73–75 For liquids, 2 h are probably sufficient and early
gastric emptying has to be accounted for.76
Several protocols for 13C‐based gastric emptying tests have been
successfully validated in comparison with scintigraphy. The medium‐
chain fatty acid, 13C‐octanoic acid,77,78 or the edible blue‐green
algae, 13C‐Spirulina platensis79 are typically used to label solids; 13C‐
acetate is used for liquids.80,81 On delivery to the duodenum, the
13C‐containing substrate is either absorbed directly (octanoic acid,
acetate) or digested and then absorbed (Spirulina). Subsequently, it is
metabolized in the liver, and finally excreted by the lungs as 13CO2.
6
The first use of the 13C‐OABT in adults was published by Ghoos
et al. in 1993.77 Gastric half emptying time (T½) was assessed by NLR
analysis and corrected for the expected delay caused by postgastric
processes (absorption, metabolization, exhalation). The authors
observed an excellent correlation between 13C‐OABT parameters
and parameters obtained from simultaneous scintigraphy (R = 0.89
for T½ scintigraphy vs. breath test). Sensitivity and specificity, posi-
tive and negative predictive values of breath test parameters for
delayed gastric emptying were ≥94%.77 Results of the 13C‐OABT also
closely correlate with those of scintigraphy in other studies in adults
and children.78,82–84 Following this initial study, all kinds of variation
of the test meal and the test protocol have been described,
depending on cultural differences and practical considerations (e.g.,
muffins, pancakes, rolls). In addition, different mathematical analysis
methods have been proposed77,80,85–88 (also compare Table 6).
Pancakes marked with 13C‐octanoic acid are an acceptable and
palatable solid test meal for children but cannot be used in case of
allergy to egg, milk or wheat, in coeliac disease or very young
children.78,88,89
The lack of standardization is of concern because it makes
comparison of values between different laboratories difficult. On the
other hand, it allows flexibility in research projects to measure gastric
emptying of very different test meals and evaluate the impact of
composition on gastric emptying.
Results of the 13C‐Spirulina‐GEBT also show high concordance
(R = 0.86) with scintigraphic data.90 The protocol is exactly defined
and has been validated in a large group of healthy volunteers and
TAB L E 5 Indications for gastric emptying testing in adults and children6,7,65,71,72
Grade of recommendation
Adults High/moderate Symptoms suggestive of gastroparesis* without evidence of mucosal or structural disease
explaining these symptoms (*nausea, vomiting, early satiety, postprandial fullness,
bloating, upper abdominal pain)
Unexplained impairment of blood glucose control in patients with diabetes mellitus, even in
the absence of abdominal symptoms (because of the central role of gastric emptying for
regulation of postprandial glycemia)
Moderate To support the diagnosis of dumping syndrome
Low Severe gastroesophageal reflux disease unresponsive to acid suppressants (particularly
before fundoplication); systemic sclerosis; after lung transplantation; Parkinson
disease; generalized GI motility disorders; patients under consideration for intestinal or
colonic surgery or transplantation because of motility disorders
Children High/moderate Most common GI symptoms located in the upper GI tract suggestive for gastroparesis:
Nausea, vomiting and abdominal pain
Low Less frequent GI symptoms located in the upper GI tract suggestive for gastroparesis: Early
satiety, postprandial fullness and bloating
Abbreviation: GI, gastrointestinal.






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































KELLER ET AL. - 609
patients.90 The test was approved by the FDA for evaluation of
gastric emptying in 2015 (https://www.accessdata.fda.gov/scripts/
cdrh/cfdocs/cfpma/pma.cfm?id=P110015), and it is also CE marked
according to the producer's information (https://sercon‐instruments.
com/wp‐content/uploads/2017/06/019‐gebt.pdf). However, it has
not been marketed in Europe, so far.
13C‐acetate has been used as a marker for acaloric and
caloric liquids such as formula diets.81,87,91–93 In young children or
children dependent on gastrostomy feeding, the test meal often
consists of milk or milk‐based formulas.94 Apple juice has also
been used.32 Results of the test closely correlate with those of
scintigraphy in adults and children.81,87,91–93 Delayed gastric
emptying of solids usually precedes disturbances in gastric
emptying of liquids.95 Therefore, tests of solid gastric emptying
are supposed to have a higher sensitivity. However, gastric
emptying of liquids can be abnormal in patients with normal
gastric emptying of solids.96 Moreover, liquid test meals are
obviously more useful in young children81,94 and probably also for
confirmation of rapid gastric emptying in patients with suspected
dumping syndrome.6,97
Intra‐individual and inter‐individual variabilities of all 13C‐GEBTs
are high in adults and children, but similar to variations observed
with scintigraphy85,88–90,94,98 and, therefore, reflect day‐to‐day
physiological variability in gastric emptying.6
How should 13C‐GEBT be performed?
Recommendation 3.2 13C‐GEBT (gastric emptying breath test) per-
formed for clinical reasons have to adhere strictly to standardized
study protocols adequately validated in a representative patient
population. This refers to preparation of the test meal as well as
test performance and evaluation of test results (for examples
compare Table 6) (97%, 0%; Q:C S:A).
As discussed above, 13C‐GEBT are indirect tests that involve
multiple steps and are prone to influences caused by demographic,
physiological, and other parameters.39,99,104 It has been hypothesized
that 13C‐GEBT might be inaccurate in conditions associated with
substantial malabsorption, liver, or lung diseases, though this is not
substantiated by clinical studies.39,44,47 However, it is still important
that tests are validated not only in healthy adults and children, but
also in the relevant patient population.77–79,81,84
Moreover, alterations of marker substance, dose or other com-
ponents of the test meal markedly influence test results. For instance,
a larger labelled test meal will result in higher normal ranges for T½
and gastric lag time.39,82,105 For 13C‐acetate an interaction has been
demonstrated between the rate of 13C‐delivery to the duodenum and
13C‐recovery in breath.33
Different mathematical models have been developed for analysis
of gastric emptying curves derived from breath tests, in particular the
NLR model, the generalized linear regression (GLR) model and the
Wagner–Nelson method.77,79,106 Cumulative 13CO2‐excretion over
time is inversely related but analogous to the scintigraphic gastric
emptying curve. However, 13CO2‐excretion does not only depend on
gastric emptying velocity but also on postgastric absorption and
metabolisation of the substrate and CO2‐exhalation rates. For this
reason, Ghoos et al. developed the original NLR model.77 According
to this model, T½ indicates the time at which half of the 13CO2 is
excreted, relative to the cumulative excretion when time is infinite.
Accordingly, results are determined by the shape of the exhalation
curve, independent of absolute 13CO2‐excretion. Measurements are
usually performed over 4 h with breath samples at 15 min intervals.
The GLR model published by Lee et al. proposed a minimum
number (N = 3) of breath samples at pre‐specified times during the
3 h postprandial period to mathematically predict the gastric
emptying endpoints measured by simultaneous scintigraphy.79 Re-
sults reflect absolute 13CO2‐excretion. A similar model with breath
samples obtained upon completion of the meal and then at 45, 90,
120, 150, 180, and 240 min postprandially was suggested by the
same group90 and is used for analysis of the test commercially
available in the USA.
The Wagner–Nelson method has been suggested for analysis of
13C‐GEBT by Sanaka et al.106 This method has been developed to
describe the entrance of ingested drugs into the venous system
based on its urinary excretion data. When applied on breath tests, it
describes the manner in which 13CO2 appears in the venous system
based on pulmonary 13CO2 excretion data.
106,107 It is used less
frequently, and, similar to the NLR model, the 13CO2‐exhalation
curve must exhibit the decreasing portion during the sampling period
for correct estimation of gastric emptying parameters.108 Accord-
ingly, breath sampling has to be routinely performed for 4 h and
potentially longer in gastroparetic patients.
Given that in Europe there is no standardized, well‐validated test
kit commercially available, and that tests are usually prepared on site,
it is of pivotal importance that clinicians adhere strictly to stan-
dardized study protocols including established analysis methods.
Especially in children, a large variety of test meals have been
explored in accordance with the variable requirements of different
age groups.78,101–103,109–114 However, several of these studies were
performed in small patient groups. Examples of well validated 13C‐
GEBT protocols in adults and children (studies with N ≥ 20) are
given in Table 6.
How should patients prepare for the test?
Recommendation 3.3 Before and during the test, precautions as
described in General Methodology (avoidance of 13C‐rich food,
avoidance of physical activity, and 13C‐rich infusions during test)
have to be observed (100%, 0%; Q:C S:A).
Recommendation 3.4 Drugs with potential influence on gastrointestinal
transit should be avoided before the test, unless essential long term
medication is concerned or the test is performed to monitor the
drug effect on gastric emptying (100%, 0%; Q:C S:B).
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Recommendation 3.5 Adult patients, older children, and adolescents
have to be fasted overnight (94%, 0%; Q:C S:A).
Recommendation 3.6 A shorter fasting period can be sufficient in very
young children (92%, 0%; Q:C S:B).
Dietary and other restrictions, which generally apply before and
during 13C‐breath testing, have been explained in General Method-
ology. Physical activity, in particular, has to be avoided during 13C‐
GEBT, not only to standardize CO2‐production but also because
physical activity influences gastric emptying velocity.43,115 Tests
should preferentially be performed in the sitting position since the
supine position may be associated with slower gastric emptying.116
Experts agree that solid test meals should be consumed within 10–
15 min, liquids within 5–10 min.
Adults, adolescents and older children are required to fast
overnight prior to breath testing77,79,88; more precisely, a fasting
period of ≥12 h is recommended by experts in adults as questionable
results have been obtained in patients eating large meals very late.
Fasting duration varies between 8 and 12 h in children and 3–4 h in
infants less than 12 months old, depending on the clinical scenario.81
Drugs which influence gastric motor function should be avoided
before the test. This includes established prokinetics as well as drugs
with anticholinergic properties (e.g., tricyclic antidepressants),
smooth muscle relaxants, and opioids. The duration of withdrawal
depends on the half‐life of the drug, 48–72 h are usually sufficient.
However, in a patient with dyspeptic symptoms, who requires long‐
term medication with, for example, amitriptyline, it is not reason-
able to alter the normal clinical situation by discontinuation of the
drug before the test.
As 13C‐GEBT are harmless, they can be performed repeatedly
and have been used successfully to monitor drug effects in clinical
studies and individual patients.117–120
How should test results be reported?
Recommendation 3.7 To allow for reliable interpretation of test results
the following parameters should be reported: assessment of gastric
emptying of solids versus liquids; marker substance; caloric content
of the test meal; duration of breath sampling period; test result
including normal values; and interpretation (accelerated, normal,
delayed gastric emptying) with T½ being the best established and
most widely used parameter (94%, 0%; Q:D S:B).
Results can be calculated from breath test data alone, not cor-
rected for scintigraphy15,20 or given as scintigraphic equivalent
values (for T½) according to Ghoos et al.13
Recommendation 3.8 The test report could be complemented by
including composition and preparation of the test meal, breath
sampling intervals, methods used for analysis, and additional
gastric emptying parameters such as T lag and GEC (gastric
emptying coefficient) with normal values (86%, 0%; Q:D S:C).
These recommendations are based on the expert consensus
that a minimum of information on methodology and test results
including normal ranges and interpretation (accelerated/normal/
delayed gastric emptying of solids/liquids) is required for reliable
interpretation. Further information on methodological aspects and
inclusion of several outcome parameters could improve diag-
nostic gain.
13C‐PANCREATIC FUNCTION TESTS
In adults, chronic pancreatitis, pancreatic cancer, and surgical pro-
cedures are the most common causes of PEI, whereas in children,
cystic fibrosis is of particular relevance. In these diseases, inflam-
matory destruction, pancreatic atrophy, ductal obstruction, or
resection of pancreatic tissue lead to decreased exocrine secretion.
Furthermore, PEI can be caused by regulatory imbalances in the
presence of a normal pancreas, such as reduced hormonal and vagal
stimulation of pancreatic secretion or inactivation of pancreatic en-
zymes in the intestinal lumen due to hyperchlorhydria (e.g.,
Zollinger–Ellison syndrome).49
Due to the large reserve capacity of the pancreas, mild to
moderate exocrine insufficiency is frequently not associated with
clinical symptoms, and overt steatorrhea is not expected unless the
secretion of pancreatic lipase is reduced to less than 10% of normal
(severe PEI). However, patients with “compensated” PEI also have an
increased risk of nutritional deficiencies, in particular, of lipid‐soluble
vitamins with respective clinical consequences.7
Indications for pancreatic function testing in adults and children as
recommended by international guidelines are given in Table 7.7,121–124
When should 13C‐PFBT be utilized?
Recommendation 4.1 The 13C‐mixed triglyceride breath test is to be
regarded as an established alternative to other non‐invasive and
invasive pancreatic function tests (97%, 0%; Q:A S:A).
Several breath tests using 13C‐labeled lipids, proteins, or com-
plex carbohydrates have been developed that indirectly assess
pancreatic lipase, protease, and amylase activities.11,12,14,100,127–136
Tests investigating lipid digestion and absorption are preferred
because, from a clinical point of view, steatorrhea is by far the most
important digestive malfunction in PEI: It is generally more severe
and develops several years prior to malabsorption of protein or
starch49 and can be associated with decreased absorption of lipid‐
soluble vitamins, as mentioned above. Indeed, a 13C‐breath test us-
ing naturally enriched maize starch lacks sensitivity and specificity
for diagnosis of PEI.136
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Tests with various 13C‐labeled lipids have been investigated, in
which triolein, trioctanoin, tripalmitin, cholesteryl‐octanoate, and
mixed triglycerides (MTG) are used to generate marker sub-
stances.128 Currently, the original127 or modified versions11,12,14,133
of the 13C‐MTGBT developed by Vantrappen et al. are almost
exclusively used in the clinic because of practical advantages (e.g.,
shorter labeled fatty acid allowing for shorter breath sampling
period). It is based on the principle that intestinal triglyceride ab-
sorption requires prior hydrolysis by pancreatic lipase to produce
free fatty acids and mono‐acyl‐glycerol. These metabolites are
incorporated into micelles, absorbed, resynthesized, and transported
to the liver. Hepatic enzymes subsequently release fatty acids,
including 13C‐octanoic acid, that is specifically bound to the Sn‐2
position of 13C‐mixed triglycerides (13C‐MTG: 1,3 distearyl 2[13C‐
octanoyl] glycerol). 13C‐octanoic acid then undergoes β‐oxidation,
which results in the formation of 13CO2, which is absorbed into the
bloodstream, transported to the lung, and exhaled. The increase in
13CO2‐concentration in breath thus correlates with pancreatic lipase
secretion.
Direct comparison with the reference standard (determination of
pancreatic enzyme and/or bicarbonate output in duodenal aspirates
following exogenous stimulation with secretin ± cerulein) demon-
strates high sensitivity for severe exocrine insufficiency (90%–100%)
with specificity ranging between 80% and 90% in adults.121,137 A
modified test using comparably high lipid loads in subjects explicitly
avoiding physical activity during testing reached high sensitivity and
specificity rates even in mild to moderate PEI (100% and 92%,
respectively).12
However, as evident from the test principle, the 13C‐MTGBT is a
test of lipid digestion and absorption. Therefore, the 13C‐MTGBT is
accepted as an appropriate alternative to the coefficient of fat
absorption, both for the diagnosis of PEI and for evaluating the ef-
ficacy of pancreatic enzyme replacement therapy (PERT) in clinical
practice.7,11,132,133,138 On the other hand, 13CO2 exhalation is not
only decreased by lipase deficiency but also by other causes of lipid
malabsorption, for example, celiac disease, short bowel syndrome, or
postcibal asynchrony following gastric resection.139 Thus, the speci-
ficity of the test for the differential diagnosis of chronic diarrhea is
limited.
Unfortunately, fecal elastase, the other noninvasive test which is
predominantly used for pancreatic function testing in the clinic, also
has limited specificity in these cases.137 Direct comparisons between
13C‐MTGBT and fecal elastase favor the 13C‐MTGBT for diagnosis of
steatorrhea,140 and generally in patients with chronic pancreatitis
after pancreatic resections.141
In infants with cystic fibrosis, sensitivity of the 13C‐MTGBT for
diagnosis of steatorrhea was high, but specificity was low.142 Thus,
the test has been mainly, though not exclusively,143,144 used to
evaluate the efficacy of PERT in children with cystic fibrosis.145
How should 13C‐PFBT be performed?
Recommendation 4.2 13C‐MTGBT performed for clinical reasons have
to adhere strictly to standardized study protocols adequately
validated in a representative patient population. This refers to
preparation of the test meal as well as test performance and
evaluation of test results (for examples compare Table 8) (100%,
0%; Q:C S:A).
Recommendation 4.3 Adult patients, adolescents and older children
have to be fasted overnight (97%, 0%; Q:C S:A).
TAB L E 7 Indications for pancreatic function testing in adults and children7,121–126
Grade of recommendation
Adults High Suspected pancreatic exocrine insufficiency in patients with pancreatic disease/after
pancreatic resection
Patients with chronic pancreatitis at the time of diagnosis (and annually thereafter if not
tested positive for pancreatic exocrine insufficiency)
Moderate Monitoring of pancreatic enzyme replacement therapy in patients with an inadequate
therapeutic responsea
Suspected pancreatic exocrine insufficiency without evidence of pancreatic disease
Differential diagnosis of chronic diarrhea
Children High Screening for pancreatic exocrine insufficiency of children with chronic pancreatitis every
6–12 months
Newly diagnosed CF
Every 3–12 months (age dependent) in CF patients with pancreatic sufficiency at time of
diagnosis
In CF patient with subnormal weight development
Abbreviation: CF, cystic fibrosis.
aonly applicable for indirect tests measuring digestion/absorption.
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Recommendation 4.4 A shorter fasting period can be sufficient in very
young children (95%, 0%; Q:C S:B).
Recommendation 4.5 Before and during the test, precautions as
described in general methodology have to be taken into account
(avoidance of 13C‐rich food, avoidance of physical activity and
13C‐rich infusions during test) (100%, 0%; Q:D S:C).
Compared to 13C‐GEBT, 13C‐MTGBT uses significantly lower
amounts of 13C resulting in lower DOB values and lower cumulative
13C‐exhalation rates. Consequently, avoidance of confounders such
as 13C‐rich food is of particular importance when conducting the 13C‐
MTGBT. Test results were not affected by liver disease in children
with cystic fibrosis.147
While adults and older children are required to fast overnight
prior to breath testing,11,12,127,132,133 a shorter period may be suffi-
cient in very young children. In analogy to gastric emptying studies,
3‐4 h of fasting are recommended in infants less than 12 months old,
depending on the clinical scenario.81
A mathematical correction for altered CO2‐production rates in
physically active subjects using heart rate recordings improves
diagnostic accuracy of the 13C‐MTGBT in non‐resting subjects.148
However, under clinical conditions, it is pragmatic to request that
patients remain seated throughout the test.
Recommendation 4.6 Drugs with potential influence on gastrointestinal
transit and/or lipid digestion and absorption should be avoided
before the test. The duration of withdrawal depends on the half‐
life of the drug, 48–72 h are usually sufficient (91%, 3%; Q:C S:B).
Recommendation 4.7 Pancreatic enzyme replacement therapy should be
avoided 2 days before the test, unless the test is performed for
monitoring the therapeutic efficacy of pancreatic enzyme
replacement therapy (97%, 0%; Q:B S:B).
Intraluminal lipolysis of the marker and lipid absorption require
prior delivery of the test meal into the duodenum, adequate mixing of
the marker, meal nutrients and digestive secretions and regulated
transport of chyme through the small intestine. Therefore, drugs,
which accelerate (e.g., prokinetics, potent laxatives) or markedly
inhibit (e.g., opioids) GI transit, may alter test results and should be
avoided before the test, unless essential long‐term medication is
concerned. Depending on the half‐life of the drug, 48–72 h of with-
drawal are usually sufficient. However, some test protocols deliber-
ately include administration of metoclopramide in order to accelerate
gastric emptying and to shorten the required breath sampling
period.11,132,149
If the 13C‐MTGBT is performed to assess the presence of PEI, it
is obvious that subjects have to stop oral PERT prior to testing. To
account for potentially slow GI transit, it is recommended that pa-
tients abstain from PERT for 2 days before the test.
On the other hand, 13C‐MTGBT is a suitable and established
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PERT.11,132 To answer this question, subjects are allowed to continue
with their usual enzyme replacement therapy. Indeed, it has been
shown that PERT can be optimized by repetitive testing with
increasing PERT doses until normal 13C‐MTGBT results are achieved.
By this, a significant increase of body weight was observed.11
How should test results be reported?
Recommendation 4.8 To allow for reliable interpretation of test results,
the following parameters should be reported: marker substance,
test results and interpretation including normal values. Cumulative
13C‐recovery rate (in % of dose administered) represents the
established main outcome parameter (94%, 0%; Q:D S:B).
Recommendation 4.9 The test report can be complemented by including
the 13C‐exhalation curve, composition and preparation of the test
meal, breath sampling intervals, methods used for analysis and
interpretation of the 13C‐exhalation with respect to the clinical
context (91%, 0%; Q:D S:B).
These recommendations are based on the expert consensus that
a minimum of information on test methodology and test results
including normal ranges and interpretation (normal/decreased in-
testinal lipolysis compatible with PEI) is required for reliable inter-
pretation. Further information regarding methodological aspects and
interpretation of test results with respect to the individual clinical
context could further improve the diagnostic validity.
13C‐LIVER FUNCTION BREATH TESTS
Established parameters for the assessment of liver function under
routine clinical conditions are measurement of bilirubin, albumin,
liver enzymes and parameters of coagulation factor synthesis in
serum or plasma, respectively. Clinical prognostic grading systems
(e.g., Child–Pugh score, Model for End‐stage Liver Disease score)
combine several of these biochemical parameters including clinical
symptoms of advanced liver cirrhosis.150
In contrast to these “static” liver function tests, “dynamic”
quantitative tests measure the elimination of a substance, which is
cleared and/or metabolized almost exclusively by the liver via
specific metabolic pathways in subcellular compartments, for
example, by cytochromes for microsomal liver function or cytosolic
or mitochondrial enzymes. 151 Accordingly, these tests constitute a
more accurate measure of the specific aspects of liver function.
Established dynamic quantitative liver function tests are the
indocyanine green clearance test and the galactose elimination ca-
pacity test.150 13C‐LFBT also represent dynamic tests with oral
consumption or intravenous application of the marker substance
and measurement of the end product of hepatic metabolism, that is
exhaled 13CO2. Some modifications have been shown to detect
early changes in liver metabolic capacity in patients, prior to the
presence of structural damage to the liver (i.e., inflammation,
fibrosis),152 though with limited sensitivities and specificities.153–160
Still, the dynamic nature of 13C‐LFBT, their possible versatility in
terms of assessing a range of different liver functions, and the ease
with which they can be repeated to follow relative changes in liver
function with time, generally imply a marked potential for clinical
application.40
When should 13C‐LFBT be utilized?
Recommendation 5.1 13C‐liver function breath tests could be used for
measurement of various aspects of liver function in adults (94%,
0%; Q:A S:C).
Recommendation 5.2 Presently, due to very limited evidence, perfor-
mance of 13C‐liver function breath tests for clinical reasons cannot
be recommended in children (95%, 0%; Q:D S:B)
Different 13C‐LFBT have been developed for assessment of he-
patic mitochondrial (substrates: 13C‐ketoisocaproate, [methyl‐13C]‐
methionine), microsomal (13C‐methacetin, 13C‐aminopyrine, [3‐meth-
yl‐13C]‐caffeine) and cytosolic (13C‐phenylalanine) function.152,157,159–
168 These have been mainly used in patients with liver fibrosis and
cirrhosis due to nonalcoholic fatty liver disease,152,157,159–
161,163,164,169,170 chronic hepatitis C,162,165 cirrhosis,166,171 and he-
patocellular carcinoma.172 Additional potential fields of application
are in steatohepatitis,156,157,159 fatty liver,160,163,169 and assessment
of prognosis in chronic liver diseases, in general: In a 7‐year pro-
spective follow‐up study in 132 patients with chronic HCV infection,
the 40‐O‐13C‐methacetin breath was not inferior to liver biopsy in
predicting liver‐related death and transplantation.173 Although
several studies have reported close correlations between 13C‐LFBT
and histological alterations or other established parameters in
adults, they have still not entered the mainstream of clinical practice
but are used exclusively by highly specialized centers. For instance,
the effect of transarterial chemoembolization on liver function has
been monitored by 13C‐methacetin test,174 and several studies sug-
gest that this test could also be used for planning of hepatic re-
sections.175–177
Given that, as yet, few studies have been performed involving
small groups of children with rare diseases,178–181 the use of 13C‐
LFBT for clinical purposes cannot be recommended in the pediatric
population, so far.
How should 13C‐LFBT be performed?
Recommendation 5.3 13C‐liver function breath tests performed for
clinical purposes have to adhere strictly to standardized and
adequately validated study protocols. This refers to preparation of
the patient, test meal/solution, test performance and evaluation of
test results (for examples compare Table 9) (100%, 0%; Q:C S:A).
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For most validated test protocols, the marker substance is
dissolved in up to 200 ml of water or unsweetened tea; breath
samples are collected before drinking of the test solution and at
regular intervals for up to 1.5 h postprandially. As shown in Table 9,
cumulative percentage of the marker dose exhaled at the end of the
observation period is the primary outcome parameter of the vast
majority of tests. The list of tests detailed in the table is incomplete
but concentrates on examples for test protocols using different
marker substances, which have been validated in an adequate pa-
tient population and have established normal or cut off values for
specific diagnoses. Apart from tests with oral marker application,
the LIMAx test177 is commercially available in some European
countries, which uses intravenous application of 40‐O‐13C‐
methacetin. For this test, the manufacturer's instructions have to
be followed exactly.
Recommendation 5.4 Before and during the test precautions as
described in general methodology have to be observed (avoidance
of 13C‐rich food, of physical activity, and of 13C‐rich infusions)
(100%, 0%; Q:C S:A).
Recommendation 5.5 Drugs with potential influence on gastrointestinal
transit and/or cytochrome p450 metabolism should be avoided
before and during the test (96%, 0%; Q:C S:B).
Recommendation 5.6 As far as essential long‐term medication is con-
cerned, it can be necessary to perform 13C‐liver function breath
tests despite ongoing medication as long as these medications are
not administered during the test period (93%, 0%; Q:B S:B).
As discussed before, potential confounders of test results
detailed in general methodology have to be avoided. For 13C‐LFBT
that investigate cytochrome P450 enzymes, drugs with potential in-
fluence on cytochrome P450 metabolism are of particular rele-
vance,182–184 and it may be necessary to perform a test despite
ongoing medication.
Especially for the most frequently applied test substrate 13C‐
methacetin, strong CYP1A2 inhibitors (e.g., ciprofloxacin, fluvox-
amin) will have an influence on hepatic methacetin metabolism,
although no interaction studies have been systematically performed.
Influences of weak CYP1A2 inhibitors (e.g., norfloxacin, propranolol)
have not been reported. However, due to the rather short duration of
the tests (no longer than 2 h for most protocols), administration
during the test period can usually be circumvented, even if essential
long‐term medication is concerned.
How should test results be reported?
Recommendation 5.7 To allow for reliable interpretation of test results
the following parameters should be reported: marker substance;
test results and interpretation including normal values (93%, 0%;
Q:D S:B).
Recommendation 5.8 The test report could be complemented by
including the 13C‐exhalation curve, composition and preparation of
the test meal/solution, breath sampling intervals, methods used for
analysis, and interpretation of test results with respect to the
clinical context (82%, 0%; Q:D S:C).
As for other 13C‐breath tests, these recommendations are based
on the expert consensus that a minimum of information on meth-
odology and test results including normal ranges and interpretation is
required for reliable interpretation. Further information regarding
methodological aspects and interpretation of test results with
respect to the individual clinical context could further improve the
diagnostic validity.
OTHER 13C‐BREATH TESTS
The 13C‐breath tests discussed in the previous chapters have
gastroenterological indications and are either clinically established or
at least used regularly by specialized centers. Apart from these, there
is a multitude of other test options at various developmental stages
for gastroenterological indications and 13C‐breath tests, which are
used by other medical specialties. Examples for these are detailed in
Table 10 and demonstrate the very broad potential applicability of
13C‐breath test technology.
CONCLUSIONS AND FUTURE PERSPECTIVES
This consensus‐based clinical practice guideline aims to assist phy-
sicians and provide them with the information required to perform
high quality 13C‐breath tests for patients with various GI symptoms
and diseases. In a consensus process, in which representatives from
all regions of Europe and specialists representing European scientific
societies participated, the available evidence was evaluated, taking
account of local facilities, diverse clinical practice, and health care
environments. Patient involvement was not covered in our guideline
because of its focus on diagnostic recommendations. However, after
publication of the guideline, a qualitative and quantitative assess-
ment of guideline adoption into clinical practice is planned, including
patient and public involvement.
The guideline gives an overview over general methodology of
13C‐breath testing and provides recommendations for the use of 13C‐
breath tests to diagnose H. pylori infection, measure gastric emptying
time and monitor pancreatic exocrine and liver function in adult and
pediatric patients. Other potential applications of 13C‐breath testing
are summarized briefly. The recommendations specifically detail
when and how individual 13C‐breath tests should be performed
including examples for well‐established test protocols.
13C‐breath tests are indirect tests and mostly require several
digestive and metabolic steps that ultimately lead to the exhalation
of 13C‐enriched breath, including intestinal absorption, hepatic
metabolization, and pulmonary excretion. Therefore, demographic
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parameters, concomitant diseases, and/or medication affecting these
processes may confound breath test results. In fact, studies have
shown that the influence of concomitant diseases on many 13C‐
breath tests is small or can be prevented by adaptation of the
breath test protocol. Information on general 13C‐breath test meth-
odology as detailed in the guideline will help clinicians to optimize
patient selection and preparation and to better understand and
interpret breath test results for individual patients.
As depicted in Figure 2, 13C‐UBT has excellent sensitivity and
specificity for diagnosis of H. pylori infection, superior to most other
tests, it is highly standardized and well established in the clinic. 13C‐
GEBT and 13C‐PFBT are validated and accepted tests for diagnosis of
gastric emptying disturbances and PEI, respectively. So far, their wide
spread use has been hampered by the lack of standardization among
centers, whichwe aim to improve by this guideline.Moreover, the tests
are currently not commercially available in Europe, so that test meals
need to be prepared on site. 13C‐LFBT are currently used by highly
specialized centers, only. They have the potential to measure various
aspects of liver function, including assessment of prognosis in chronic
liver disease. However, their clinical role, in general, and applicability in
pediatric patients, in particular, still need to be established.
Apart from identification of this and other areas of future
research, the guideline should improve pan‐European harmonization
of diagnostic approaches to symptoms and disorders, which are very
common in specialist and primary care gastroenterology practice,
both in adult and pediatric patients.
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TAB L E 10 Examples of other 13C‐breath tests
References Estimated parameter Remarks
(185–194) Insulin resistance, metabolic syndrome 13C‐glucose + unmarked glucose (e.g., 75 g) dissolved in water, outcome parameters:
Cumulative 13CO2‐exhalation, maximal DOB‐value, 13C‐exhalation at specific time
point
13C‐exhalation is significantly decreased in patients with impaired insulin resistance/
metabolic syndrome, site of labeled carbon atom in glucose molecule is relevant for
metabolic results
Breath test described as valid surrogate index of clamp‐derived measures of insulin
resistance, with good accuracy and precision, but controversial findings regarding
applicability as screening tool (insufficient accuracy) in minority of studies
Non‐invasive tool for early diagnosis and follow up of patients in high‐risk groups
(195–198) SIBO, OCTT Lactose‐[13C]ureide, moderate sensitivity (66.7%), high specificity (100%) for SIBO in
comparison with culture from jejunal aspirates, glucose‐[13C]ureide could be used
alternatively
Bacterial metabolism of marker is prerequisite for 13CO2‐exhalation, increase caused by
SIBO or arrival of the marker substance in the colon
Predosing with unlabelled ureide is frequently part of the protocol, induces enzyme
induction, increases rate of 13CO2‐recovery but complicates procedure
(136,199–201) PEI (amylase deficiency)
Congenital sucrase‐isomaltase deficiency
Maize starch is naturally enriched with 13C, 50–100 g used as pancreatic function test, but
limited sensitivity (up to 77%) and specificity (up to 74%) in comparison with “gold
standard” (secretin cerulein test)
13CO2 release following labelled starch or sucrose is decreased in patients with sucrase‐
isomaltase deficiency
(202–210) Activity of drug metabolizing enzymes 13C‐erythromycin applied iv (or orally) → hepatic (and intestinal) cytochrome P450 3A4
and 3A5 (CYP3A4/5) activity in vivo, pilot studies
13C‐pantoprazole→ CYP2C19 activity, can predict the anti‐platelet efficacy of clopidogrel
(which is metabolized by CYP2C19 to its active metabolite) and high metabolization
rate of PPI
13C‐dextromethorphan → CYP2D6 activity (e.g., relevant for activation of the prodrug
tamoxifen), [2‐(13)C]uracil → dihydropyrimidine dehydrogenase (DPD) deficiency to
predict 5‐fluorouracil dose‐related toxicity
Abbreviations: DOB, δ over baseline; OCTT, oro‐cecal transit time; PEI, pancreatic exocrine insufficiency; PPI, proton pump inhibitor; SIBO, small
intestinal bacterial overgrowth.
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